Analysis and clinical findings of cases positive for the novel synthetic cannabinoid receptor agonist MDMB-CHMICA

@article{Seywright2016AnalysisAC,
  title={Analysis and clinical findings of cases positive for the novel synthetic cannabinoid receptor agonist MDMB-CHMICA},
  author={A. Seywright and H. Torrance and F. M. Wylie and D. McKeown and D. Lowe and R. Stevenson},
  journal={Clinical Toxicology},
  year={2016},
  volume={54},
  pages={632 - 637}
}
  • A. Seywright, H. Torrance, +3 authors R. Stevenson
  • Published 2016
  • Medicine
  • Clinical Toxicology
  • Abstract Context: MDMB-CHMICA is a synthetic cannabinoid receptor agonist which has caused concern due to its presence in cases of adverse reaction and death. Method: 43 cases of suspected synthetic cannabinoid ingestion were identified from patients presenting at an Emergency Department and from post-mortem casework. These were subjected to liquid-liquid extraction using tertiary-butyl methyl ether and quantitatively analysed by Electrospray Ionisation Liquid Chromatography–tandem Mass… CONTINUE READING
    18 Citations
    Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA
    • 26
    Poisoning due to MDMB-CHMICA, a synthetic cannabinoid receptor agonist
    • 6
    Blood concentrations of synthetic cannabinoids.
    • 1

    References

    SHOWING 1-10 OF 23 REFERENCES
    Toxicological findings of synthetic cannabinoids in recreational users.
    • 96
    • PDF
    SODAS: Surveillance of Drugs of Abuse Study
    • 5
    Use of Synthetic Cannabinoids in Patients With Psychotic Disorders: Case Series
    • 42
    Death due to diabetic ketoacidosis: Induction by the consumption of synthetic cannabinoids?
    • 31
    Synthetic cannabinoids
    • R. Bilici
    • Medicine
    • Northern clinics of Istanbul
    • 2014
    • 89
    • PDF
    Synthetic Cannabinoids
    • 61
    Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS.
    • 3,758
    Marijuana-based drugs: innovative therapeutics or designer drugs of abuse?
    • 112
    • PDF